Sponsored Links
| The Landmark HORIZONS-AMI Trial: Final 3 Year Results |
 |
 |
 |
| Medical News - Cardiovascular and Cardiology | |||
|
Data from the landmark HORIZONS-AMI clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a glycoprotein (GP) IIb/IIIa inhibitor in heart attack patients undergoing angioplasty after 3 years... Read more: Cardiovascular / Cardiology News From Medical News Today
|